Healthcare / Elderly CareEurope
← Sticker Wall
JOURNEY · DETAIL
Novo Nordisk: The Century-Old Insulin Specialist Becomes Europe's Market Cap King via Semaglutide
Founded: August Krogh, Marie Krogh, Hans Christian Hagedorn · Novo Nordisk A/S
JOURNEY
Key Fields
FIELD STAMPSIndustryHealthcare / Elderly Care
RegionEurope
ScaleGiant
ChannelOther
Origin
In 1922, Danish physiologist August Krogh witnessed the life-saving power of insulin in the U.S. His wife, Marie, was a diabetic herself. In 1923, they returned to Denmark to found Nordisk Insulin Laboratory. In 1925, colleagues the Hagedorn brothers established Novo. After over 60 years of fierce competition, the two merged in 1989. Controlled by the Novo Nordisk Foundation, the company's mission is deeply rooted in diabetes care, allowing it to focus on one thing for a century: perfecting metabolic disease treatments, which ultimately led to its breakthrough in the GLP-1 space.
Milestones
1923
Founding Turning Point
After winning the Nobel Prize in Physiology, August Krogh visited the U.S. in 1923, secured the production license for insulin in Northern Europe, and returned home to start production. His wife, Marie Krogh, a scholar in Type 2 diabetes and metabolism, provided the personal motivation that ignited this century-old pharmaceutical enterprise.
1989
Merger Transition
In 1989, after six decades of rivalry, Novo and Nordisk officially merged to form Novo Nordisk. By unifying R&D and production pipelines, it became the European insulin leader and maintained the top global market share in diabetes medication, building the unique expertise in protein engineering and large-scale fermentation capacity essential for future GLP-1 development.
2017
PMF PMF
In 2017, semaglutide was approved in the U.S. as Ozempic for Type 2 diabetes, with its once-weekly injection convenience outperforming daily competitors. The weight-loss version, Wegovy, was approved in 2021, showing an average clinical weight loss of about 15%. Boosted by celebrity endorsements like Elon Musk, the two products combined for over $20 billion in sales in 2023, and in September 2023, the company's market cap surpassed LVMH to become Europe's largest listed company.
2024
Setback Failure
The Phase 3 clinical trial for the next-generation weight-loss drug CagriSema achieved only about 22.7% weight loss, falling short of the market's 25% expectation. The stock price plummeted nearly 20% in a single day, wiping out nearly $100 billion in market value and exposing the company's pipeline anxiety under pressure from Eli Lilly's tirzepatide data.
2025
Leadership Change Turning Point
In 2025, with the stock price retreating over 50% from its peak and a market cap loss of approximately $450 billion over two years, CEO Lars Fruergaard Jørgensen, who served for over 30 years, was asked by the board to step down. His successor, Maziar Mike Doustdar, cut costs and accelerated the oral weight-loss pipeline, visiting China in 2026 to announce the filing for oral semaglutide.
2026
Battle Transition
The core patent for semaglutide in China lasts until April 2027, and several Chinese generic firms have already completed Phase 3 filings. Novo Nordisk China head Cai Yan has publicly emphasized the company's original drug moat and new strategy. While the company maintained double-digit revenue growth in 2025 and semaglutide remains the primary revenue pillar, the shift in growth engines and pricing pressure are the biggest uncertainties for 2026.
Turning Points
- 2017: Ozempic approval allows the century-old insulin firm to enter the $100 billion-plus obesity market.
- 2023: Market cap surpasses LVMH to lead Europe, forcing the company to transition from a chronic disease expert to a capacity and supply chain-driven enterprise.
- December 2024: CagriSema data misses expectations, triggering a single-day crash and shifting market sentiment from faith to scrutiny.
- 2025: CEO change and cost restructuring signal the end of the 'golden era' and the start of a defensive, consolidation phase.
Failures & Pitfalls
- CagriSema Phase 3 weight-loss data of ~22.7% fell below market expectations, leading to a nearly $100 billion market cap loss in one day in December 2024.
- The U.S. market faces a pincer attack from compounded semaglutide pharmacies and Eli Lilly's tirzepatide, leading to multiple earnings guidance cuts in 2025.
- Market cap retreated over 50% from its 2024 peak, cited by media as one of the most severe market value evaporations in European history.
- The development pace of oral weight-loss drugs lagged behind competitors, forcing the company to rely on accelerated Chinese filings to catch up.
关键成功要素
- A century of focus on diabetes and metabolic diseases, with 30 years of GLP-1 technical accumulation finally paying off.
- Innovation in once-weekly injection formulations and barriers in protein engineering production capacity.
- The Novo Nordisk Foundation's holding structure provides long-term 'patient capital' for R&D.
- Celebrity effects and the obesity narrative perfectly captured the public sentiment of the social media era.
- Proactive layout of original drug status and new formulations in key markets like China ahead of the patent cliff.
Lessons
- A blockbuster product can propel a company to the peak, but it can also trap the company in single-product risk.
- Clinical data missing expectations is a multi-billion dollar disaster in capital markets; pipeline expectation management is mandatory.
- The patent cliff waits for no one; the transition to the next generation of products and markets must be completed during the protection period.
- The core asset of a century-old firm is not a specific molecule, but 30 years of focus on a single disease area.
- Supply chain and production capacity are the 'last mile' in turning scientific breakthroughs into cash flow.
Core Data
- 2023 Revenue：Approx. 232.3 billion DKK (approx. $34 billion) (Public data, not independently verified)
- 2024 Revenue：Approx. 290.4 billion DKK (Public data, not independently verified)
- 2023 Market Cap Peak：Approx. $428 billion, surpassing LVMH (Public data, not independently verified)
- Market Cap Evaporation：Retreated over 50% from 2024 peak, losing approx. 3 trillion RMB over two years (Public data, not independently verified)
- Semaglutide Series Annual Sales：Over $20 billion in 2023 (Public data, not independently verified)
- Single Product Revenue Share：Semaglutide series is the primary revenue pillar, accounting for over half (Public data, not independently verified)
- Employee Count：Approx. 77,000 globally (Public data, not independently verified)
- Patent Milestone：Core semaglutide patent in China protected until April 2027 (Public data, not independently verified)
Competitors / Peers
The primary global rival is Eli Lilly, whose tirzepatide (Zepbound and Mounjaro) has pressured Novo Nordisk, with weight-loss data occasionally outperforming semaglutide and overtaking it in prescription share in 2025. Legacy firms like Amgen, Roche, and AstraZeneca are also ramping up their weight-loss pipelines. In China, GLP-1 generics and innovative drugs from companies like Huadong Medicine, Innovent Biologics, and Hengrui Medicine have completed Phase 3 trials, ready to flood the market when the patent expires in April 2027. Novo Nordisk's moat lies in its century-old fermentation capacity, brand trust, and first-mover advantage in oral formulations, but the end of the duopoly's 'easy growth' era is now a certainty.